

# MARAPHARM

CSE:MDM FSE:2M0 OTCQB:MRPHF

Kelowna, British Columbia

[info@marapharm.com](mailto:info@marapharm.com) Telephone: 778-583-4476

## News Release

**November 8, 2016 - Marapharm announces how it's affected by the results of the Nevada Marijuana Legalization Initiative, which is on the ballot November 8, 2016**

Kelowna, British Columbia, Canada – November 8, 2016.

Marapharm ticker symbols: Canada - CSE:MDM / Germany - FSE:2M0 / United States - OTCQB:MRPHF) – Marapharm Ventures Inc. ("Marapharm") announces that it is updating shareholders and interested parties on its Nevada operations about any impact from the vote to whether to allow recreational use for marijuana.

On November 8, 2016 Question 2 is on the ballot in Nevada as an indirect initiated State statute. A "yes" vote supports the proposal to legalize marijuana for recreational use for individuals 21 and over and a "no" vote opposes the proposal.

"Marapharm owns 5.9 acres of industrial land in Las Vegas and has an accepted offer to purchase an adjoining 1.1 acres. Special Use Permits have been granted for 3 medical marijuana licenses totaling 300,000 square feet. Development has commenced and 2 starter buildings are expected to be completed and in production within a few months" says Linda Sampson, CEO. She continued with "all of our production and cultivation is pre-sold for medical purposes so the outcome of Question 2 doesn't affect us at the present time, however the

expectation is that we will be able to also supply the recreational market at some point in the near future if the Nevada Marijuana Legalization Initiative for recreational use is a "yes" vote. The bottom line is that at the present time it really doesn't make any difference to Marapharm whether the vote is yes or no, our business in Nevada is great."

#### **ABOUT MARAPHARM VENTURES INC.**

[www.marapharm.com](http://www.marapharm.com)

Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website ([www.thecse.com](http://www.thecse.com)), the OTC website ([www.otcmarkets.com](http://www.otcmarkets.com)) and Sedar website ([www.sedar.com](http://www.sedar.com)) under the profile for Marapharm Ventures Inc.

#### **FOR FURTHER INFORMATION:**

[www.marapharm.com](http://www.marapharm.com) or Linda Sampson, CEO, 778-583-4476  
[info@marapharm.com](mailto:info@marapharm.com)

#### **STOCK EXCHANGES:**

***Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.***

#### **FORWARD - LOOKING STATEMENTS:**

Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.

